Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

被引：0

作者：

Giulia Bon

Laura Pizzuti

Valentina Laquintana

Rossella Loria

Manuela Porru

Caterina Marchiò

Eriseld Krasniqi

Maddalena Barba

Marcello Maugeri-Saccà

Teresa Gamucci

Rossana Berardi

Lorenzo Livi

Corrado Ficorella

Clara Natoli

Enrico Cortesi

Daniele Generali

Nicla La Verde

Alessandra Cassano

Emilio Bria

Luca Moscetti

Andrea Michelotti

Vincenzo Adamo

Claudio Zamagni

Giuseppe Tonini

Giacomo Barchiesi

Marco Mazzotta

Daniele Marinelli

Silverio Tomao

Paolo Marchetti

Maria Rosaria Valerio

Rosanna Mirabelli

Antonio Russo

Maria Agnese Fabbri

Nicola D’Ostilio

Enzo Veltri

Domenico Corsi

Ornella Garrone

Ida Paris

Giuseppina Sarobba

Francesco Giotta

Carlo Garufi

Marina Cazzaniga

Pietro Del Medico

Mario Roselli

Giuseppe Sanguineti

Isabella Sperduti

Anna Sapino

Ruggero De Maria

Carlo Leonetti

Angelo Di Leo

机构：

[1] IRCCS Regina Elena National Cancer Institute,Cellular Network and Molecular Therapeutic Target Unit

[2] IRCCS Regina Elena National Cancer Institute,Division of Medical Oncology 2

[3] IRCCS Regina Elena National CancerInstitute,Pathology Department

[4] IRCCS Regina Elena National Cancer Institute,Area of Translational Research

[5] University of Turin,Department of Medical Sciences

[6] Candiolo Cancer Institute,Medical Oncology

[7] FPO-IRCCS,Radiotherapy Unit, Department of Oncology

[8] Sandro Pertini Hospital,Medical Oncology Unit

[9] Oncology Clinic,Department of Medical, Oral and Biotechnological Sciences

[10] “Ospedali Riuniti di Ancona” Hospital,Department of Medical Oncology

[11] Careggi University Hospital,Oncology Unit, IRCCS Foundation Polyclinic University A. Gemelli

[12] St Salvatore Hospital,Department of Oncology and Hematology

[13] University Gabriele D’Annunzio,Medical Oncology Unit, A.O. Papardo & Department of Human Pathology

[14] University La Sapienza,Medical Oncology Unit, Addarii Institute of Oncology

[15] Breast Cancer Unit,Department of Oncology

[16] ASST Cremona,Medical Oncology Unit

[17] Oncology Unit,Department of Radiological, Oncological and Anatomo

[18] ASST Fatebenefratelli Sacco-PO Fatebenefratelli,Pathological Sciences

[19] University Cattolica Del Sacro Cuore,Medical Oncology

[20] University of Verona,Department of Ematology & Oncology

[21] University Hospital,Medical Oncology Unit

[22] UO Medical Oncology,Medical Oncology Unit

[23] S. Chiara Hospital,Gynaecology – Oncology Unit

[24] University of Messina,Department of Medical Oncology

[25] S. Orsola-Malpighi Hospital,Division of Medical Oncology

[26] University Campus Biomedico,Department of Systems Medicine

[27] Sant’Andrea University Hospital,Radiotherapy Department

[28] University La Sapienza,Department of Medical Oncology

[29] Umberto I University Hospital,Scientific Direction

[30] Paolo Giaccone University Hospital,undefined

[31] Pugliese-Ciaccio Hospital,undefined

[32] Medical Oncology Unit,undefined

[33] Belcolle Hospital,undefined

[34] Medical Oncology Unit,undefined

[35] Lanciano-Vasto,undefined

[36] Santa Maria Goretti Hospital,undefined

[37] Fatebenefratelli Hospital,undefined

[38] Medical Oncology AO S. Croce and Carle Teaching Hospital,undefined

[39] University Cattolica del Sacro Cuore,undefined

[40] Department of Medical Oncology,undefined

[41] ASL Nuro,undefined

[42] IRCCS Giovanni Paolo II,undefined

[43] Division of Medical Oncology,undefined

[44] Pescara Hospital,undefined

[45] Research Unit Phase I Trials and Oncology Unit,undefined

[46] ASST,undefined

[47] Reggio Calabria General Hospital,undefined

[48] Medical Oncology,undefined

[49] University Tor Vergata,undefined

[50] IRCCS Regina Elena National Cancer Institute,undefined

来源：

Journal of Experimental & Clinical Cancer Research | / 39卷

关键词：

HER2+ breast cancer; Trastuzumab/pertuzumab blockade; T-DM1 efficacy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
Bon, Giulia
Pizzuti, Laura
Laquintana, Valentina
Loria, Rossella
Porru, Manuela
Marchio, Caterina
Krasniqi, Eriseld
Barba, Maddalena
Maugeri-Sacca, Marcello
Gamucci, Teresa
Berardi, Rossana
Livi, Lorenzo
Ficorella, Corrado
Natoli, Clara
Cortesi, Enrico
Generali, Daniele
La Verde, Nicla
Cassano, Alessandra
Bria, Emilio
Moscetti, Luca
Michelotti, Andrea
Adamo, Vincenzo
Zamagni, Claudio
Tonini, Giuseppe
Barchiesi, Giacomo
Mazzotta, Marco
Marinelli, Daniele
Tomao, Silverio
Marchetti, Paolo
Valerio, Maria Rosaria
Mirabelli, Rosanna
Russo, Antonio
Fabbri, Maria Agnese
D'Ostilio, Nicola
Veltri, Enzo
Corsi, Domenico
Garrone, Ornella
Paris, Ida
Sarobba, Giuseppina
Giotta, Francesco
Garufi, Carlo
Cazzaniga, Marina
Del Medico, Pietro
Roselli, Mario
Sanguineti, Giuseppe
Sperduti, Isabella
Sapino, Anna
De Maria, Ruggero
Leonetti, Carlo
Di Leo, Angelo
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
[2] HER2 expression and efficacy of T-DM1
Montemurro, Filippo
BREAST CANCER RESEARCH, 2014, 16 (06):
[3] HER2 expression and efficacy of T-DM1
Filippo Montemurro
Breast Cancer Research, 16
[4] Sparing chemotherapy with dual HER2 blockade in combination with endocrine therapy for advanced HER2 positive breast cancer
Werutsky, Gustavo
Reinert, Tomas
Fay, Andre Poisl
TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S573 - S576
[5] Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature
Martinez, Maria Teresa
Perez-Fidalgo, Jose Alejandro
Martin-Martorell, Paloma
Cejalvo, Juan Miguel
Pons, Vanesa
Bermejo, Begona
Martin, Miguel
Albanell, Joan
Lluch, Ana
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 97 : 96 - 106
[6] HER2 missense mutations in breast cancer cells do not alter HER2 internalization or sensitivity to T-DM1
Akamatsu, Hiroaki
Mino, Rosa
Mettlen, Marcel
Ye, Dan
Sudhan, Dhivya R.
Lin, Albert
Marin, Arnaldo
Servetto, Alberto
Lee, Kyung-min
Chatterjee, Sumanta
Schmid, Sandra L.
Arteaga, Carlos L.
Hanker, Ariella B.
CANCER RESEARCH, 2020, 80 (16)
[7] Dual HER2 Blockade
Thomssen, Christoph
El Saghir, Nagi S.
Francis, Prudence A.
Jassem, Jacek
Rugo, Hope S.
Untch, Michael
BREAST CARE, 2017, 12 (05) : 345 - 349
[8] HER2 status in breast cancer patients: A comparison between borderline positive HER2 and strongly positive HER2 tumors
Huszno, J.
Nowara, E.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S137 - S137
[9] T-DM1 for HER2 positive advanced breast cancer: a single institution, "real life" experience
Bertolini, I.
Ferrarini, I.
Fancelli, S.
De Angelis, C.
Fontana, A.
Salvadori, B.
Landucci, E.
Michelotti, A.
Falcone, A.
ANNALS OF ONCOLOGY, 2015, 26 : 20 - 21
[10] HER2 positive breast cancer
Gianni, Luca
Bianchini, Giampaolo
CANCER RESEARCH, 2023, 83 (05)

← 1 2 3 4 5 →